TABLE 1.
Demographics and baseline characteristics of inpatients admitted to Johns Hopkins Medicine in eras 1 and 2
| Era 1 (March 1, 2020–May 31, 2020) | Era 2 (June 1, 2020–November 30, 2020) | P | |
|---|---|---|---|
| N | 21 | 56 | |
| Length of stay, median (IQR), d | 8 (5–9) (n = 21) | 6 (3–10) (n = 55) | 0.5 |
| Age, median (IQR), y | 55 (48–63) | 56 (43–67) | 0.9 |
| Biological female, n (%) | 9 (42.9) | 23 (41.1) | 1.0 |
| Gender, n (%) | 1.0 | ||
| Male | 12 (57.1) | 32 (57.1) | |
| Female | 9 (42.9) | 23 (41.1) | |
| Other | 0 (0.0) | 1 (1.8) | |
| Race, n (%) | 0.055 | ||
| Indigenous/Black | 0 (0.0) | 1 (1.8) | |
| Asian | 1 (4.8) | 0 (0.0) | |
| Black or African Descent | 11 (52.4) | 23 (41.1) | |
| White or Caucasian | 6 (28.6) | 30 (53.6) | |
| Other | 3 (14.3) | 2 (3.6) | |
| Hispanic, n (%) | 5 (23.8) | 7 (12.5) | 0.29 |
| Organ category, n (%) | 0.8 | ||
| Kidney | 12 (57.1) | 29 (51.8) | |
| Liver | 4 (19.0) | 12 (21.4) | |
| Heart | 2 (9.5) | 3 (5.4) | |
| Lung | 2 (9.5) | 10 (17.9) | |
| Hand | 0 (0.0) | 1 (1.8) | |
| Kidney/liver | 1 (4.8) | 1 (1.8) | |
| Mo since transplant, median (IQR) | 54 (18–119) | 63 (27–113) | 0.7 |
| Diabetes, n (%)a | 13 (61.9) | 28 (50.0) | 0.44 |
| HTN, n (%)a | 17 (81.0) | 43 (76.8) | 0.8 |
| CAD, n (%)a | 2 (9.5) | 7 (12.5) | 1.0 |
| CHF, n (%)a | 2 (9.5) | 8 (14.3) | 0.7 |
| Malignancy, n (%)a | 2 (9.5) | 5 (8.9) | 1.0 |
| CKD, n (%)a | 7 (33.3) | 21 (37.5) | 0.8 |
| Dialysis, n (%)a | 4 (19.0) | 5 (8.9) | 0.25 |
| Cirrhosis, n (%)a | 3 (14.3) | 1 (1.8) | 0.059 |
| Lung disease, n (%)a | 0 (0.0) | 16 (28.6) | 0.004 |
| HIV, n (%)a | 0 (0.0) | 4 (7.3) | 0.6 |
| Graft dysfunction, n (%)a | 9 (42.9) | 28 (50.0) | 0.6 |
| MMF use at baseline, n (%) | 13 (61.9) | 30 (53.6) | 0.6 |
| MMF discontinued, n (%) | 13 (100.0) | 30 (100.0) | n/a |
| Death, n (%) | 1 (4.8) | 4 (7.1) | 1.0 |
aComorbidities present immediately before the coronavirus disease 2019 episode, not pretransplant.
CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; HIV, human immunodeficiency virus; HTN, hypertension; IQR, interquartile range; MMF, mycophenolate mofetil.